New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocyt ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

In a significant move within the biopharmaceutical sector, Sanofi has once again turned to Dren Bio, committing an impressive $100 million upfront for further development of B cell depletion therapies ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...

Dren Bio, a privately held, clinical-stage biotechnology company, has entered a strategic collaboration with Sanofi for the discovery and development of a next-generation B-cell depleting therapy to ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi to develop therapies ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...

Amid positive trial results, ZYNLONTA has already received accelerated approval from the FDA and conditional approval from ...